These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

662 related articles for article (PubMed ID: 32284036)

  • 21. Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections.
    Huang J; Tang YQ; Sun JY
    Scand J Infect Dis; 2010 Apr; 42(4):260-5. PubMed ID: 20085424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.
    Zavascki AP; Goldani LZ; Li J; Nation RL
    J Antimicrob Chemother; 2007 Dec; 60(6):1206-15. PubMed ID: 17878146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.
    Falagas ME; Kasiakou SK
    Clin Infect Dis; 2005 May; 40(9):1333-41. PubMed ID: 15825037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. History, Chemistry and Antibacterial Spectrum.
    Velkov T; Thompson PE; Azad MAK; Roberts KD; Bergen PJ
    Adv Exp Med Biol; 2019; 1145():15-36. PubMed ID: 31364069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multidrug-resistant Gram-negative infections: the use of colistin.
    Michalopoulos AS; Karatza DC
    Expert Rev Anti Infect Ther; 2010 Sep; 8(9):1009-17. PubMed ID: 20818945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review.
    Nørgaard SM; Jensen CS; Aalestrup J; Vandenbroucke-Grauls CMJE; de Boer MGJ; Pedersen AB
    Antimicrob Resist Infect Control; 2019; 8():170. PubMed ID: 31709047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous combined with aerosolised polymyxin versus intravenous polymyxin alone in the treatment of pneumonia caused by multidrug-resistant pathogens: a systematic review and meta-analysis.
    Liu D; Zhang J; Liu HX; Zhu YG; Qu JM
    Int J Antimicrob Agents; 2015 Dec; 46(6):603-9. PubMed ID: 26607337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
    Li J; Nation RL; Milne RW; Turnidge JD; Coulthard K
    Int J Antimicrob Agents; 2005 Jan; 25(1):11-25. PubMed ID: 15620821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multidrug-resistant gram-negative infections. Bringing back the old.
    Chan-Tompkins NH
    Crit Care Nurs Q; 2011; 34(2):87-100. PubMed ID: 21407003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Agents of Last Resort: Polymyxin Resistance.
    Kaye KS; Pogue JM; Tran TB; Nation RL; Li J
    Infect Dis Clin North Am; 2016 Jun; 30(2):391-414. PubMed ID: 27208765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations.
    Ezadi F; Ardebili A; Mirnejad R
    J Clin Microbiol; 2019 Apr; 57(4):. PubMed ID: 30541939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis.
    Vardakas KZ; Falagas ME
    Int J Antimicrob Agents; 2017 Feb; 49(2):233-238. PubMed ID: 27686609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular mechanisms of polymyxin resistance: knowns and unknowns.
    Baron S; Hadjadj L; Rolain JM; Olaitan AO
    Int J Antimicrob Agents; 2016 Dec; 48(6):583-591. PubMed ID: 27524102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Colistin resistance in Gram-negative ocular infections: prevalence, clinical outcome and antibiotic susceptibility patterns.
    Mitra S; Basu S; Rath S; Sahu SK
    Int Ophthalmol; 2020 May; 40(5):1307-1317. PubMed ID: 31984448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multidrug-resistant Gram-negative bacteria: how to treat and for how long.
    Giamarellou H
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S50-4. PubMed ID: 21129924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
    Kasiakou SK; Michalopoulos A; Soteriades ES; Samonis G; Sermaides GJ; Falagas ME
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3136-46. PubMed ID: 16048915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous colistin for the management of multidrug-resistant bacterial infections in Indian patients.
    Wilfred PM; Chandy SJ; Rebecca G; Satyendra S; Jasmine S
    Trop Doct; 2021 Jul; 51(3):301-306. PubMed ID: 33491607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rescuing the Last-Line Polymyxins: Achievements and Challenges.
    Nang SC; Azad MAK; Velkov T; Zhou QT; Li J
    Pharmacol Rev; 2021 Apr; 73(2):679-728. PubMed ID: 33627412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam - epidemiology, laboratory detection and treatment implications.
    Sherry N; Howden B
    Expert Rev Anti Infect Ther; 2018 Apr; 16(4):289-306. PubMed ID: 29543500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New information about the polymyxin/colistin class of antibiotics.
    Molina J; Cordero E; Pachón J
    Expert Opin Pharmacother; 2009 Dec; 10(17):2811-28. PubMed ID: 19929704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.